Mohammad Hirmand
2021
In 2021, Mohammad Hirmand earned a total compensation of $5.6M as Chief Medical Officer at Turning Point Therapeutics, a 713% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $263,500 |
|---|---|
| Option Awards | $2,803,338 |
| Salary | $480,250 |
| Stock Awards | $2,027,765 |
| Other | $40,019 |
| Total | $5,614,872 |
Hirmand received $2.8M in option awards, accounting for 50% of the total pay in 2021.
Hirmand also received $263.5K in non-equity incentive plan, $480.3K in salary, $2M in stock awards and $40K in other compensation.
Rankings
In 2021, Mohammad Hirmand's compensation ranked 2,271st out of 12,406 executives tracked by ExecPay. In other words, Hirmand earned more than 81.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,271 out of 12,406 | 82nd |
Division Manufacturing | 885 out of 5,492 | 84th |
Major group Chemicals And Allied Products | 339 out of 2,368 | 86th |
Industry group Drugs | 293 out of 2,089 | 86th |
Industry Pharmaceutical Preparations | 189 out of 1,536 | 88th |
Source: SEC filing on April 29, 2022.
Hirmand's colleagues
We found six more compensation records of executives who worked with Mohammad Hirmand at Turning Point Therapeutics in 2021.
2021
Athena Countouriotis
Turning Point Therapeutics
Chief Executive Officer
2021
Annette North
Turning Point Therapeutics
General Counsel
2021
Paolo Tombesi
Turning Point Therapeutics
Chief Financial Officer
2021
Siegfried PHD
Turning Point Therapeutics
Chief Scientific Officer
2021
Yi Larson
Turning Point Therapeutics
Chief Financial Officer
2021
Brian Baker
Turning Point Therapeutics